513
Participants
Start Date
July 31, 2006
Primary Completion Date
November 30, 2012
Study Completion Date
November 30, 2012
ceftriaxone
"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
placebo
an inactive substance
Beth Israel Medical Center (NY), New York
Cornell Medical Center, New York
Columbia University, New York
Albany Medical Center, Albany
SUNY Upstate Medical University, Syracuse
Allegheny Hospital, Pittsburgh
University of Pittsburgh, Pittsburgh
Pennsylvania State University, Hershey Medical Center, Hershey
Drexel University College of Medicine (Hahnemann Campus), Philadelphia
University of Pennsylvania, Philadelphia
George Washington University, Washington D.C.
University of Virginia, Charlottesville
Wake Forest University School of Medicine, Winston-Salem
Carolinas Medical Center, Charlotte
Medical University of South Carolina, Charleston
ALS Center at Emory University, Atlanta
Medical College of Georgia, Augusta
Mayo Clinic Jacksonville, Jacksonville
University of Miami School of Medicine, Miami
Vanderbilt University, Nashville
University of Kentucky Medical Center, Lexington
Ohio State University, Columbus
The Cleveland Clinic Foundation, Cleveland
Indiana University (Regenstrief Health Center), Indianapolis
Henry Ford Health System, Detroit
Saint Mary's Healthcare, Grand Rapids
Hennepin County Medical Center (Berman Center), Minneapolis
Northwestern University Medical School, Chicago
St. Louis University, St Louis
Washington University, St Louis
University of Kansas Medical Center, Kansas City
Bryan LGH Medical Center (University of Nebraska), Lincoln
Texas Neurology, Dallas
Methodist Neurological Institute, Houston
University of Colorado Health Sciences Center, Aurora
University of Utah Health Sciences Center, Salt Lake City
Phoenix Neurological Associates, Phoenix
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles, Los Angeles
Loma Linda University School of Medicine (CA), Loma Linda
University of California, Irvine - MDA ALS Neuromuscular Center, Orange
University of California, San Francisco- Fresno, Fresno
California Pacific Medical Center, San Francisco
University of California, San Francisco, San Francisco
University of California, Davis, Davis
Oregon Clinic (Providence Clinic), Portland
Hospital for Special Care, New Britain
Massachusetts General Hospital, Boston
Lahey Clinic, Burlington
UMDNJ- Robert Wood Johnson School of Medicine, New Brunswick
University of Calgary, Calgary
Univeristy of Alberta ALS Clinic, Edmonton
Dalhousie University, Halifax
London Health Sciences Center, University Campus, London
University of Toronto, Toronto
CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital, Montreal
Montreal Neurological Institute (McGill University), Montreal
Laval University, Québec
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Massachusetts General Hospital
OTHER